SMTI vs BLCO vs HSIC vs ATRC

For growth investors, Sanara MedTech Inc.

(SMTI) is the stronger pick with 19. 0% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Sanara MedTech Inc. (SMTI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Henry Schein, Inc.

is actually cheaper at 13. 3x.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -12. 5%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: SMTI returned +218. 0% versus BLCO's -20. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Henry Schein, Inc.

(HSIC) is the lower-risk stock at 0. 73β versus Sanara MedTech Inc. 's 1. 42β — meaning SMTI is approximately 94% more volatile than HSIC relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 8% for Sanara MedTech Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanara MedTech Inc.

(SMTI) is pulling ahead at 19. 0% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -282. 5% for Sanara MedTech Inc.. Over a 3-year CAGR, SMTI leads at 31. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -36. 4% for Sanara MedTech Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMTI leads at 7. 1% versus -0. 6% for ATRC. At the gross margin level — before operating expenses — SMTI leads at 92. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Henry Schein, Inc.

(HSIC) trades at 13. 3x forward P/E versus 370. 7x for AtriCure, Inc. — 357. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Henry Schein, Inc.

(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Both have compounded well over 10 years (HSIC: +5. 3%, BLCO: -20. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SMTI is a small-cap high-growth stock; BLCO is a small-cap quality compounder stock; HSIC is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.